Page last updated: 2024-11-13

combivent respimat

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Albuterol, Ipratropium Drug Combination: A combined pharmaceutical preparation of Ipratropium Bromide and Albuterol Sulfate that is used to treat the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID24847804
MeSH IDM000603239

Synonyms (8)

Synonym
combivent respimat
albuterol sulfate / ipratropium bromide
albuterol, ipratropium drug combination
1031840-23-9
albuterol / ipratropium
8-azoniabicyclo(3.2.1)octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, bromide (1:1), (3-endo,8-syn)-, mixt. with alpha1-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-1,3- benzenedimethanol sulfate (2:1)
duolin
4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;(8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate;sulfuric acid;bromide

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Risk of major adverse cardiovascular events was similar for both regions."( TIOtropium Safety and Performance In Respimat
Anzueto, A; Bai, C; Boonsawat, W; Isidro, MG; Lee, KH; Mahayiddin, AA; Metzdorf, N; Moon, HS; Mueller, A; Zhong, N, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
" Assessment of 1-second forced expiratory volume (FEV1) curves before and after dosing on the last day of each 2-week period indicated that the combination was superior to either single agent in peak effect and area under the curve up to 8 h after dosing (FEV1-AUC0-8), in both phases of the trial."( Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group.
Coleman, W; Gross, N; Linberg, S; Miller, R; Oren, J; Tashkin, D, 1998
)
0.3
" Further studies are necessary to confirm the optimum dosing regimen in asthma."( Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma.
Beeh, KM; Fležar, M; Gahlemann, M; LaForce, C; Toorawa, R; Wenz, A, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (3.57)18.2507
2000's4 (14.29)29.6817
2010's23 (82.14)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 101.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index101.92 (24.57)
Research Supply Index3.83 (2.92)
Research Growth Index5.42 (4.65)
Search Engine Demand Index179.84 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (101.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (36.36%)5.53%
Reviews5 (15.15%)6.00%
Case Studies2 (6.06%)4.05%
Observational1 (3.03%)0.25%
Other13 (39.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]